Population pharmacokinetics and pharmacodynamics of dalfampridine-ER in healthy volunteers and in patients with multiple sclerosis

Author： Weir Scott   Gao Yuying   Henney Herbert R.  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.29, Iss.12, 2013-12, pp. : 1637-1645

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis

By Weir Scott   Torkin Risa   Henney III Herbert R.  

Current Medical Research and Opinion, Vol. 29, Iss. 12, 2013-12 ,pp. : 1627-1636

Informa Healthcare

Access to resources Recommend Favorite

First Clinical Experience with TRV027: Pharmacokinetics and Pharmacodynamics in Healthy Volunteers

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 53, Iss. 9, 2013-09 ,pp. : 892-899

John Wiley & Sons Inc

Access to resources Recommend Favorite

PK and PD of peginterferon beta‐1a in multiple sclerosis patients

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 79, Iss. 3, 2015-03 ,pp. : 514-522

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis

By Dunn Jeffrey   Blight Andrew  

Current Medical Research and Opinion, Vol. 27, Iss. 7, 2011-07 ,pp. : 1415-1423

Informa Healthcare

Access to resources Recommend Favorite

Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers

By Krishnan Suma M.   Stark Jeffrey G.  

Current Medical Research and Opinion, Vol. 24, Iss. 1, 2008-01 ,pp. : 33-40

Informa Healthcare

Access to resources Recommend Favorite